Over the past 20 years, rheumatologists have developed and witnessed many paradigmatic changes not only in the medication of rheumatoid arthritis (RA) but also in other autoimmune rheumatic diseases. With regard to RA, less joint damage and better physical function has been demonstrated as a consequence of an early institution of disease-modifying anti-rheumatic drugs. Furthermore, the definition of core set variables and developments of composite measurements to assess RA have allowed disease activity to be assessed reliably. Finally, new biologic active agents have shown to be of major importance for fulfilling the aim of low disease activity or even remissions, specifically if treatment is commenced at a very early stage of the disease.
These obvious significant advances in the treatment options for RA and other autoimmune rheumatic diseases would not have been made possible without a new culture for conducting clinical trials starting in the mid-1980s.
The book Clinical Trials in Rheumatology provides a comprehensive overview of trials in different rheumatic diseases. It presents many important clinical trials conducted over the last 40 years, ranging from complex, double-blinded or open multicentric trials, e.g., the BeSt-study to case studies in situations where real trials are still missing.
The different clinical trials to rheumatologic disease entities as listed in the book are not directly comparing outcome and clinical efficacy, or giving therapeutic recommendations. (For therapeutic decisions, the authors recommend to follow national and international guidelines and ongoing discussions concerning different treatment strategies in different autoimmune rheumatic diseases.) Instead, the book presents a well-founded and comprehensive selection of the most important studies. The authors present the relevant information concerning study design, medications, patient populations, clinical endpoints, and adverse events, thus offering a quick overview on the clinical trials conducted in different autoimmune rheumatic diseases.This new form of presenting the significant data of the most important studies in a comparable form renders this book a valuable help in the constantly growing multitude of clinical data in rheumatology.
How to Read This Book
Trials are listed by disease according to the table of contents. In ANCA-associated vasculitis, at the beginning of a trial summary, different disease entities are listed if the trial investigated a mixture of vasculitides affecting vessels of different sizes according to the CHC-definitions. The sequence within a disease is corticosteroid trials at the beginning, followed by non biologic DMARDs in alphabetical order and trials with biologics, again alphabetically, after DMARD-trials. Several trials with one substance are presented in chronological order, beginning with the earliest.
Contents
- Acronym-finder
- Rheumatoid Arthritis
- Corticosteroids
- Atorvastatin
- Azathioprine
- Azathioprine vs. Methotrexate
- Hydroxychloroquine vs. Sulphasalazine
- Hydroxychloroquine
- Chloroquine vs. Ciclosporin
- Ciclosporin
- Ciclosporin vs. Chloroquine
- Ciclosporin vs. parenteral Gold
- Ciclosporin
- Ciclosporin vs. Methotrexate
- Ciclosporin vs. Azathioprine
- Cyclophosphamide
- Gold vs. Methotrexate
- Gold vs. Cyclophosphamide vs. Azathioprine
- Leflunomide
- Leflunomide vs. Sulfasalazine
- Methotrexate vs. Leflunomide
- Leflunomide
- Sulfasalazine vs. Leflunomide
- Leflunomide
- Leflunomide vs. Methotrexate
- Leflunomide
- Leflunomide vs. Methotrexate
- Methotrexate
- Sulfasalazine
- Sulfasalazine vs. Gold
- Sulfasalazine
- Tacrolimus
- Early DMARD therapy
- Ciclosporin + Chloroquine
- Methotrexate + Hydroxychloroquine
- Methotrexate + Doxycycline
- Methotrexate + Sulfasalazine
- Methotrexate + Ciclosporin
- Methotrexate + Hydroxychloroquine + Sulfasalazine
- Methotrexate + Leflunomide
- Methotrexate + Azathioprine
- Gold + Methotrexate
- Gold + Hydroxychloroquine
- Abatacept
- Etanercept + Abatacept
- Adalimumab
- Anakinra
- Certolizumab pegol
- Etanercept
- Anakinra + Etanercept
- Golimumab
- Infliximab
- Infliximab vs. Etanercept
- Anti-TNF
- Rituximab
- Tocilizumab
- Ankylosing Spondylitis
- Methylprednisolone
- Cyclophosphamide
- Leflunomide
- Methotrexate
- Pamidronate
- Sulfasalazine
- Pred., Cyc., 5FU, MTX, MMF
- Adalimumab
- Etanercept
- Infliximab vs. Etanercept
- Golimumab
- Infliximab
- Psoriatic Arthritis
- Chloroquine
- Ciclosporin vs. Methotrexate
- Ciclosporine vs. Sulfasalazine
- Ciclosporin ± Methotrexate
- Leflunomide
- Leflunomide vs. Methotrexate
- Methotrexate
- Sulfasalazine
- Adalimumab
- Alefacept
- Etanercept
- Golimumab
- Infliximab
- Ustekinumab
- Systemic Lupus Erythematosus
- Corticosteroids
- Azathioprine
- Azathioprine vs. Ciclosporin
- Chloroquine and Hydroxychloroquine
- Hydroxychloroquine + Mycophenolate Mofetil
- Cyclophosphamide vs. Azathioprine
- Cyclophosphamide Followed by Azathioprine
- Cyclophosphamide
- Cyclophosphamide Followed by Azathioprine
- Cyclophosphamide
- Cyclophosphamide vs. Azathioprine
- Leflunomide
- Methotrexate
- Mycophenolate Mofetil vs. Cyclophosphamide, Azathioprine
- Mycophenolate Mofetil
- Mycophenolate or Azathioprine after Cyclophosphamide
- Tacrolimus
- Infliximab
- Rituximab
- Antiphospholipid Syndrome
- Aspirin
- Aspirin vs. Heparin
- Aspirin + Heparin
- Aspirine + Prednisone
- Aspirine vs. Prednisone
- Heparin
- Heparin vs. Prednisone
- Heparin vs. intravenous Immunoglobulin
- Intravenous Immunoglobulins
- Warfarin
- Progressive Systemic Sclerosis
- Corticosteroids
- Ambrisentan
- Azathioprine
- Azathioprine + Cyclophosphamide
- Bosentan
- Chlorambucil
- Ciclosprine
- Colchicine
- Cyclophosphamide
- Cyclophosphamide vs. Azathioprine
- Cyclophosphamide
- D-Penicillamine
- Methotrexate
- Mycophenolate Mofetil
- 5-Fluorouracil
- Etanercept
- Rituximab
- Plasma Exchange
- Stem Cell Transplantation
- Autologous Stem Cell Transplantation
- Raynaud’s Phenomenon
- Diltiazem
- Glycerol Trinitrate
- Iloprost
- Nifedipine
- Sildenafil
- Dermato/Polymyositis
- Corticosteroids
- Azathioprine
- Cyclosphosphamide
- Immunoglobulins
- Methotrexate
- Methotrexate vs. Ciclosporine
- Mycophenolate Mofetil
- Anti-TNF
- Etanercept
- Rituximab
- Plasma Exchange
- Sjögren’s syndrome
- Hydroxychloroquine
- Leflunomide
- Methotrexate
- Mycophenolate
- Pilocarpine
- Etanercept
- Infliximab
- Rituximab
- Takayasu Arteritis
- Methotrexate
- Mycophenolate mofetil
- Infliximab and Etanercept
- Anti-TNF
- Giant Cell Arteritis
- Corticosteroids
- Azathioprine
- Ciclosporin
- Methotrexate
- Etanercept
- Infliximab
- Polymyalgia Rheumatica
- Azathioprine
- Corticosteroids
- Methotrexate
- Etanercept
- Infliximab
- ANCA-Associated Vasculitis, Churg Strauss syndrome,
- Polyarteritis Nodosa, and other vasculitic entities
- Azathioprine
- Co-trimoxazole
- Cyclophosphamide
- Methotrexate
- Mycophenolate mofetil
- Anti-Thymocyte Globulin
- Etanercept
- Immunoglobulins
- Infliximab
- Rituximab
- Plasma Exchange
- Purpura Schoenlein Henoch
- Corticosteroids
- Azathioprine
- Ciclosporin
- Cyclophosphamide
- Morbus Behçet
- Corticosteroids
- Azathioprine
- Ciclosporin vs. Colchicine
- Ciclosporine
- Ciclosporin vs. Cyclophosphamide
- Colchicine
- Cyclophosphamide vs. Colchicine
- Dapsone
- Methotrexate
- Mycophenolate mofetil
- Tacrolimus
- Thalidomide
- Etanercept
- Infliximab
- Interferon alfa-2b
- Interferon alfa-2a
- Abbreviations
- Index
Product Details
- Hardcover: 747 pages
- Publisher: Springer; 1st edition (January 25, 2011)
- Language: English
- ISBN-10: 1849963835
- ISBN-13: 978-1849963831
- Product Dimensions: 9.3 x 6.5 x 2 inches